6:25 PM
 | 
May 09, 2016
 |  BC Extra  |  Top Story

NewLink's IMPRESS results disappoint

NewLink Genetics Corp. (NASDAQ:NLNK) sank $5.50 (33%) to $11 in early after-hours trading Monday after it said HyperAcute Pancreas algenpantucel-L missed the primary overall survival endpoint in the Phase III IMPRESS study to treat resected pancreatic cancer. Median survival among patients treated with algenpantucel-L plus standard of care (SOC) was 27.3 months vs. 30.4 months for SOC alone...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >